TARA Stock Risk & Deep Value Analysis

Protara Therapeutics Inc

Healthcare • Biotechnology

DVR Score

4.8

out of 10

Proceed with Caution

What You Need to Know About TARA Stock

We analyzed Protara Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran TARA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.

Updated Mar 12, 2026•Run Fresh Analysis →

How Risky Is TARA Stock?

Overall Risk

Aggressive

Financial Risk

High

Market Risk

Low

Competitive Risk

Low

Execution Risk

High

Regulatory Risk

Medium

What Are the Red Flags for TARA?

⚠
Negative or inconclusive Phase 3 trial results for TARA-002.
⚠
Inability to secure sufficient future funding, leading to significant dilution or operational slowdown.
⚠
Adverse safety signals from ongoing trials.
⚠
Competitor developing an alternative therapy for LM.

Unlock TARA Red Flags & Risk Warnings

Create a free account to see the full analysis

What Does Protara Therapeutics Inc (TARA) Do?

Market Cap

$243.10M

Sector

Healthcare

Industry

Biotechnology

Employees

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

Visit Protara Therapeutics Inc Website

Is TARA Stock Undervalued?

Protara Therapeutics (TARA) continues to represent a high-risk, high-reward investment opportunity, mirroring our assessment from 22 days ago. The investment thesis remains predominantly tied to the binary outcome of its lead asset, TARA-002, in the global Phase 3 trial for refractory lymphatic malformations (LM), with results still anticipated in late 2026 / early 2027. This orphan indication, coupled with Fast Track designation, signifies a substantial unmet medical need and potential for market leadership, justifying the projected 10x upside upon clinical success. However, critical concerns regarding the company's precarious financial health, characterized by a high cash burn rate, persist. This necessitates future financing rounds and carries a material risk of significant dilution, severely impacting the probability of realizing the full upside. Given no material operational or financial news has emerged since the last analysis, the overall investment thesis remains unchanged, balancing speculative long-term growth against immediate clinical and financial challenges. The current score reflects the significant potential offset by substantial inherent risks.

Unlock the full AI analysis for TARA

Get the complete DVR score, risk analysis, and more

Does TARA Have a Competitive Moat?

Moat Rating

🛡️ Narrow

Moat Trend

Expanding

Moat Sources

2 Identified

Intangible Assets/IP (patents for TARA-002)Regulatory Advantages (Orphan Drug, Fast Track)

The moat is currently nascent but has the potential to become narrow and durable if TARA-002 successfully completes Phase 3 trials and receives regulatory approval. Patent protection, market exclusivity from orphan drug status, and the inherent difficulty for competitors to replicate a successful clinical trial outcome would provide a strong, albeit time-limited, competitive advantage.

Moat Erosion Risks

•Clinical trial failure or unexpected safety issues.
•Expiration of key patents or challenges to intellectual property.
•Emergence of superior alternative therapies from competitors.
•Inability to commercialize effectively post-approval.

TARA Competitive Moat Analysis

What Could Drive TARA Stock Higher?

Near-Term (0-6 months)

•Q4 2025 Earnings Call (Estimated Early May 2026): Focus on cash runway and R&D updates.
•Clinical trial updates on TARA-002 enrollment progress (Any ad-hoc announcements).

Medium-Term (6-18 months)

•Anticipation of top-line Phase 3 trial results for TARA-002 in LM (Late 2026 / Early 2027).

Long-Term (18+ months)

•Potential regulatory submission and approval of TARA-002 for LM (2027-2028).
•Commercialization and market penetration of TARA-002 (2028+).
•Pipeline expansion or new indication development.

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

What's the Bull Case for TARA?

✓
Successful and timely completion of TARA-002 Phase 3 trial enrollment.
✓
Any positive interim data or early readouts from the TARA-002 trial.
✓
New financing rounds that demonstrate manageable dilution and extend cash runway beyond 12-18 months.
✓
Updates on regulatory interactions and potential for accelerated approval pathways.

Bull Case Analysis

See what could go right with Premium

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

Analyze Any Stock →View Top 100 Deep Value Stocks →

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for TARA (Protara Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.